Trial
NCT05338632
Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Leiden University Medical Center
Collaborators
Food and Drug Administration (FDA)
Condition
Opioid Induced Respiratory Depression
Intervention
Narcan 40 MG/ML Nasal Spray
Why stopped
Recruitment of chronic opioid users was substantially lower than anticipated despite extensive recruitment efforts; the study was therefore closed before reaching the planned sample size.
Provenance
Dataset: 2026-07-31 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-29